Italian validation and Measurement Invariance of the Food Addiction Symptom Inventory (FASI)
Abstract
Abstract Background The Food Addiction Symptom Inventory (FASI) is a clinician-administered semi-structured interview developed to assess addiction-like eating behaviors related to ultra-processed food consumption, but a validated Italian version is unavailable. This study aimed to validate the Italian version of the FASI and examine its psychometric properties and clinical correlates in a sample of patients with eating disorders (EDs). Methods One hundred and eighteen patients with anorexia nervosa-restrictive subtype and binge-eating spectrum disorder were recruited. Participants completed the FASI interview and questionnaires on eating and general disorder psychopathology (YFAS 2.0, EDE-Q, EBA-O, BES, BDI-II). Confirmatory factor analysis (CFA) tested the dimensional structure of the FASI and the measurement of invariance between diagnostic groups. Reliability and convergent validity were examined. Results CFA supported the one-factor structure of the FASI and indicated a good model fit (CFI = 0.958, TLI = 0.947, RMSEA = 0.064 and SRMR = 0.076) and internal consistency (α = 0.80). Measurement invariance analyses supported configural and partial metric invariance across restrictive- and binge-spectrum ED groups. Correlations between total FASI symptom criteria and YFAS 2.0 symptom scores supported convergent validity. Moderate-to-strong associations emerged in the overall sample (r = 0.581), with somewhat lower convergence observed in the AN group (r = 0.408) than the…
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.